Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from lamivudine to telbivudine versus continued lamivudine in adults with chronic hepatitis B
2004-003754-26Phase 3Completed
- Sponsor
- Idenix Pharmaceuticals
- Start
- Mar 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Chronic Hepatitis B (CHB) comparing Switch to telbivudine with Continue lamivudine (2 arms). Primary endpoint: Primary antiviral efficacy (HBV DNA reduction). Started Mar 2005; status: completed.
02
Drugs
telbivudinelamivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2004-003754-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003754-26.